Literature DB >> 25381132

Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts.

Elizabeth A Griffiths1, Michelle C Golding2, Pragya Srivastava3, Benjamin J Povinelli4, Smitha R James5, Laurie A Ford3, Meir Wetzler3, Eunice S Wang3, Michael J Nemeth6.   

Abstract

Entities:  

Keywords:  WNT inhibitors; WNT signaling; acute myeloid leukemia; β-catenin

Mesh：

Substances：

Year:  2014        PMID： 25381132      PMCID： PMC4803144          DOI： 10.3324/haematol.2014.113118

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.

Authors:  L Ysebaert; G Chicanne; C Demur; F De Toni; N Prade-Houdellier; J-B Ruidavets; V Mansat-De Mas; F Rigal-Huguet; G Laurent; B Payrastre; S Manenti; C Racaud-Sultan
Journal:  Leukemia       Date:  2006-05-11       Impact factor: 11.528

2.  Genomic impact of transient low-dose decitabine treatment on primary AML cells.

Authors:  Jeffery M Klco; David H Spencer; Tamara L Lamprecht; Shawn M Sarkaria; Todd Wylie; Vincent Magrini; Jasreet Hundal; Jason Walker; Nobish Varghese; Petra Erdmann-Gilmore; Cheryl F Lichti; Matthew R Meyer; R Reid Townsend; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

3.  Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia.

Authors:  Maria Simon; Victoria L Grandage; David C Linch; Asim Khwaja
Journal:  Oncogene       Date:  2005-03-31       Impact factor: 9.867

4.  The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

Authors:  Yingzi Wang; Andrei V Krivtsov; Amit U Sinha; Trista E North; Wolfram Goessling; Zhaohui Feng; Leonard I Zon; Scott A Armstrong
Journal:  Science       Date:  2010-03-26       Impact factor: 47.728

5.  An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.

Authors:  Foster C Gonsalves; Keren Klein; Brittany B Carson; Shauna Katz; Laura A Ekas; Steve Evans; Robert Nagourney; Timothy Cardozo; Anthony M C Brown; Ramanuj DasGupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-10       Impact factor: 11.205

6.  Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot.

Authors:  Orla Maguire; Christine Collins; Kieran O'Loughlin; Jeffrey Miecznikowski; Hans Minderman
Journal:  Cytometry A       Date:  2011-04-25       Impact factor: 4.355

7.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Authors:  Shih-Min A Huang; Yuji M Mishina; Shanming Liu; Atwood Cheung; Frank Stegmeier; Gregory A Michaud; Olga Charlat; Elizabeth Wiellette; Yue Zhang; Stephanie Wiessner; Marc Hild; Xiaoying Shi; Christopher J Wilson; Craig Mickanin; Vic Myer; Aleem Fazal; Ronald Tomlinson; Fabrizio Serluca; Wenlin Shao; Hong Cheng; Michael Shultz; Christina Rau; Markus Schirle; Judith Schlegl; Sonja Ghidelli; Stephen Fawell; Chris Lu; Daniel Curtis; Marc W Kirschner; Christoph Lengauer; Peter M Finan; John A Tallarico; Tewis Bouwmeester; Jeffery A Porter; Andreas Bauer; Feng Cong
Journal:  Nature       Date:  2009-09-16       Impact factor: 49.962

8.  β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.

Authors:  Jenny Yeung; Maria Teresa Esposito; Arnaud Gandillet; Bernd B Zeisig; Emmanuel Griessinger; Dominique Bonnet; Chi Wai Eric So
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

9.  Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.

Authors:  Arnaud Gandillet; Sophie Park; François Lassailly; Emmanuel Griessinger; Jacques Vargaftig; Andrew Filby; T Andrew Lister; Dominique Bonnet
Journal:  Leukemia       Date:  2011-02-22       Impact factor: 11.528

10.  Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome.

Authors:  Jinglan Xu; Momoko Suzuki; Yousuke Niwa; Junji Hiraga; Tetsuro Nagasaka; Masafumi Ito; Shigeo Nakamura; Akihiro Tomita; Akihiro Abe; Hitoshi Kiyoi; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Br J Haematol       Date:  2008-02       Impact factor: 6.998
View more
  11 in total

Review 1.  WNT Signaling in Cardiac and Vascular Disease.

Authors:  Sébastien Foulquier; Evangelos P Daskalopoulos; Gentian Lluri; Kevin C M Hermans; Arjun Deb; W Matthijs Blankesteijn
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

2.  γ-Catenin Overexpression in AML Patients May Promote Tumor Cell Survival via Activation of the Wnt/β-Catenin Axis.

Authors:  Jiejin Qian; Xianbo Huang; Yinyin Zhang; Xiujin Ye; Wenbin Qian
Journal:  Onco Targets Ther       Date:  2020-02-12       Impact factor: 4.147

3.  SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.

Authors:  Shuang Ma; Ling-Ling Yang; Ting Niu; Chuan Cheng; Lei Zhong; Ming-Wu Zheng; Yu Xiong; Lin-Li Li; Rong Xiang; Li-Juan Chen; Qiao Zhou; Yu-Quan Wei; Sheng-Yong Yang
Journal:  Sci Rep       Date:  2015-10-26       Impact factor: 4.379

4.  Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.

Authors:  Hai Yi; Dongfeng Zeng; Zhaohua Shen; Jun Liao; Xiaoguo Wang; Yao Liu; Xi Zhang; Peiyan Kong
Journal:  Oncotarget       Date:  2016-06-28

5.  LEF-1 drives aberrant β-catenin nuclear localization in myeloid leukemia cells.

Authors:  Rhys G Morgan; Jenna Ridsdale; Megan Payne; Kate J Heesom; Marieangela C Wilson; Andrew Davidson; Alexander Greenhough; Sara Davies; Ann C Williams; Allison Blair; Marian L Waterman; Alex Tonks; Richard L Darley
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

6.  HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1.

Authors:  Mandy Beyer; Annette Romanski; Al-Hassan M Mustafa; Miriam Pons; Iris Büchler; Anja Vogel; Andrea Pautz; Andreas Sellmer; Günter Schneider; Gesine Bug; Oliver H Krämer
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

Review 7.  Wnt Signalling in Acute Myeloid Leukaemia.

Authors:  Alicja M Gruszka; Debora Valli; Myriam Alcalay
Journal:  Cells       Date:  2019-11-07       Impact factor: 6.600

8.  Targeting Wnt signaling in acute myeloid leukemia stem cells.

Authors:  Felice Pepe; Marius Bill; Dimitrios Papaioannou; Malith Karunasiri; Allison Walker; Eric Naumann; Katiri Snyder; Parvathi Ranganathan; Adrienne Dorrance; Ramiro Garzon
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 11.047

Review 9.  Therapeutic Targeting of the Leukaemia Microenvironment.

Authors:  Vincent Kuek; Anastasia M Hughes; Rishi S Kotecha; Laurence C Cheung
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

Review 10.  The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Authors:  Silje Johansen; Annette K Brenner; Sushma Bartaula-Brevik; Håkon Reikvam; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.